blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2238251

EP2238251 - SILENCING OF POLO-LIKE KINASE EXPRESSION USING INTERFERING RNA [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.12.2015
Database last updated on 28.05.2024
Most recent event   Tooltip20.07.2018Lapse of the patent in a contracting state
New state(s): PT		published on 22.08.2018  [2018/34]
Applicant(s)For all designated states
Protiva Biotherapeutics Inc.
100-8900 Glenlyon Parkway
Burnaby, British Columbia V5J 5J8 / CA
[2010/41]
Inventor(s)01 / MACLACHLAN, Ian
8040 Aves Terrace
Mission British Columbia V4S 1E5 / CA
02 / JUDGE, Adam
1936 West 11th Avenue
Vancouver British Columbia V6J 2C6 / CA
 [2010/41]
Representative(s)Campbell, Patrick John Henry
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
[2015/07]
Former [2010/41]Campbell, Patrick John Henry
J.A. Kemp & Co. 14 South Square Gray's Inn
London WC1R 5JJ / GB
Application number, filing date08867007.023.12.2008
[2010/41]
WO2008CA02285
Priority number, dateUS20070017075P27.12.2007         Original published format: US 17075 P
US20080045228P15.04.2008         Original published format: US 45228 P
US20080100653P26.09.2008         Original published format: US 100653 P
[2010/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009082817
Date:09.07.2009
Language:EN
[2009/28]
Type: A1 Application with search report 
No.:EP2238251
Date:13.10.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 09.07.2009 takes the place of the publication of the European patent application.
[2010/41]
Type: B1 Patent specification 
No.:EP2238251
Date:11.02.2015
Language:EN
[2015/07]
Search report(s)International search report - published on:CA09.07.2009
(Supplementary) European search report - dispatched on:EP19.08.2011
ClassificationIPC:C12N15/113, C12N15/88, A61K31/712, A61K31/713, A61K47/48, A61K9/127, A61P35/00
[2011/38]
CPC:
C12N15/1137 (EP,US); A61K9/0019 (EP,US); A61K9/127 (EP,US);
A61K9/1271 (EP,US); A61K9/1272 (EP,US); A61P35/00 (EP);
A61P43/00 (EP); C12N15/88 (EP,US); C12Y207/11021 (EP,US);
C12N2310/14 (EP,US); C12N2310/321 (EP,US); C12N2310/322 (EP,US);
C12N2310/3231 (EP,US); C12N2310/335 (US); C12N2310/3521 (US);
C12N2310/3525 (US); C12N2310/3533 (US); C12N2320/30 (US) (-)
C-Set:
C12N2310/321, C12N2310/3521 (EP,US);
C12N2310/322, C12N2310/3525 (US,EP);
C12N2310/322, C12N2310/3533 (US,EP)
Former IPC [2010/41]C12N15/11, A61K31/7105, A61K31/712, A61K31/713, A61K47/24, A61K47/28, A61K48/00, A61K9/00, A61P35/00, C12N15/10, C12N15/87, C12N15/88, C07H21/02, C12N15/54, C12N9/12
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/41]
Extension statesAL22.07.2010
BA22.07.2010
MK22.07.2010
RS22.07.2010
TitleGerman:SILENCING DER POLO-LIKE-KINASE-EXPRESSION UNTER VERWENDUNG VON INTERFERENZ-RNA[2010/41]
English:SILENCING OF POLO-LIKE KINASE EXPRESSION USING INTERFERING RNA[2010/41]
French:SILENÇAGE DE L'EXPRESSION DE LA POLO-LIKE KINASE À L'AIDE D'UN ARN INTERFÉRENT[2010/41]
Entry into regional phase22.07.2010National basic fee paid 
22.07.2010Search fee paid 
22.07.2010Designation fee(s) paid 
22.07.2010Examination fee paid 
Examination procedure22.07.2010Examination requested  [2010/41]
16.03.2012Amendment by applicant (claims and/or description)
05.12.2012Despatch of a communication from the examining division (Time limit: M06)
06.06.2013Reply to a communication from the examining division
18.12.2013Despatch of a communication from the examining division (Time limit: M04)
26.02.2014Reply to a communication from the examining division
10.09.2014Communication of intention to grant the patent
22.12.2014Fee for grant paid
22.12.2014Fee for publishing/printing paid
22.12.2014Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  05.12.2012
Opposition(s)12.11.2015No opposition filed within time limit [2016/03]
Fees paidRenewal fee
22.11.2010Renewal fee patent year 03
12.12.2011Renewal fee patent year 04
11.12.2012Renewal fee patent year 05
12.12.2013Renewal fee patent year 06
11.12.2014Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.12.2008
AT11.02.2015
BE11.02.2015
BG11.02.2015
CY11.02.2015
CZ11.02.2015
DK11.02.2015
EE11.02.2015
HR11.02.2015
LT11.02.2015
LV11.02.2015
MC11.02.2015
MT11.02.2015
PL11.02.2015
PT11.02.2015
RO11.02.2015
SI11.02.2015
SK11.02.2015
TR11.02.2015
NO11.05.2015
GR12.05.2015
IS11.06.2015
[2018/34]
Former [2017/39]HU23.12.2008
AT11.02.2015
BE11.02.2015
BG11.02.2015
CY11.02.2015
CZ11.02.2015
DK11.02.2015
EE11.02.2015
HR11.02.2015
LT11.02.2015
LV11.02.2015
MC11.02.2015
MT11.02.2015
PL11.02.2015
RO11.02.2015
SI11.02.2015
SK11.02.2015
TR11.02.2015
NO11.05.2015
GR12.05.2015
IS11.06.2015
Former [2016/33]AT11.02.2015
BE11.02.2015
CZ11.02.2015
DK11.02.2015
EE11.02.2015
HR11.02.2015
LT11.02.2015
LV11.02.2015
MC11.02.2015
PL11.02.2015
RO11.02.2015
SI11.02.2015
SK11.02.2015
NO11.05.2015
GR12.05.2015
IS11.06.2015
Former [2016/24]AT11.02.2015
BE11.02.2015
CZ11.02.2015
DK11.02.2015
EE11.02.2015
HR11.02.2015
LT11.02.2015
LV11.02.2015
PL11.02.2015
RO11.02.2015
SI11.02.2015
SK11.02.2015
NO11.05.2015
GR12.05.2015
IS11.06.2015
Former [2016/12]AT11.02.2015
CZ11.02.2015
DK11.02.2015
EE11.02.2015
HR11.02.2015
LT11.02.2015
LV11.02.2015
PL11.02.2015
RO11.02.2015
SI11.02.2015
SK11.02.2015
NO11.05.2015
GR12.05.2015
IS11.06.2015
Former [2015/50]AT11.02.2015
CZ11.02.2015
DK11.02.2015
EE11.02.2015
HR11.02.2015
LT11.02.2015
LV11.02.2015
PL11.02.2015
RO11.02.2015
SK11.02.2015
NO11.05.2015
GR12.05.2015
IS11.06.2015
Former [2015/49]AT11.02.2015
CZ11.02.2015
DK11.02.2015
EE11.02.2015
HR11.02.2015
LT11.02.2015
LV11.02.2015
RO11.02.2015
SK11.02.2015
NO11.05.2015
GR12.05.2015
IS11.06.2015
Former [2015/39]AT11.02.2015
HR11.02.2015
LT11.02.2015
LV11.02.2015
NO11.05.2015
GR12.05.2015
IS11.06.2015
Former [2015/38]AT11.02.2015
HR11.02.2015
LT11.02.2015
NO11.05.2015
GR12.05.2015
IS11.06.2015
Former [2015/37]HR11.02.2015
LT11.02.2015
NO11.05.2015
GR12.05.2015
Former [2015/36]HR11.02.2015
LT11.02.2015
NO11.05.2015
Former [2015/35]LT11.02.2015
NO11.05.2015
Documents cited:Search[XI]US2007265438  (KHVOROVA ANASTASIA [US], et al) [X] 1-3,11-15 * paragraph [0114]; figures 10C,24; examples 2,13,17; claim 1; table 5; sequences 367,447 * [I] 4-10;
 [XI]CN1651450  (HANGZHOU XINRUIJIA BIOMEDICINE [CN]) [X] 1-3,11-15 * figure 1; examples 1,3; claims 9,13,14; sequences 19,20 * [I] 4-10;
 [A]WO2007051303  (PROTIVA BIOTHERAPEUTICS INC [CA], et al) [A] 1-15 * the whole document *;
 [I]  - AHONEN L J ET AL, "Polo-like Kinase 1 Creates the Tension-Sensing 3F3/2 Phosphoepitope and Modulates the Association of Spindle-Checkpoint Proteins at Kinetochores", CURRENT BIOLOGY, CURRENT SCIENCE, GB, vol. 15, no. 12, doi:10.1016/J.CUB.2005.05.026, ISSN 0960-9822, (20050621), pages 1078 - 1089, (20050621), XP025346426 [I] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.cub.2005.05.026
 [AD]  - ZIMMERMANN T S ET AL, "RNAi-mediated gene silencing in non-human primates", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 441, no. 7089, doi:10.1038/NATURE04688, ISSN 0028-0836, (20060504), pages 111 - 114, (20060326), XP002552050 [AD] 7-15 * the whole document *

DOI:   http://dx.doi.org/10.1038/nature04688
 [AD]  - HEYES J ET AL, "Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 112, no. 2, doi:10.1016/J.JCONREL.2006.02.012, ISSN 0168-3659, (20060515), pages 280 - 290, (20060515), XP024957509 [AD] 7-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.jconrel.2006.02.012
International search[X]US2007265438  (KHVOROVA ANASTASIA [US], et al);
 [X]CN1651450  (HANGZHOU XINRUIJIA BIOMEDICINE [CN]);
 [X]WO2004045543  (DHARMACON INC [US]);
 [Y]  - LIU X. ET AL., "Normal Cells, but Not Cancer Cells, Survive Severe Plkl Depletion.", MOL. CELL. BIOL., (2006), vol. 26, no. 6, pages 2093 - 2108, XP002482341

DOI:   http://dx.doi.org/10.1128/MCB.26.6.2093-2108.2006
 [Y]  - JUDGE, A.D. ET AL., "Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo.", MOL. THER., (2006), vol. 13, no. 3, pages 494 - 505, XP005326762

DOI:   http://dx.doi.org/10.1016/j.ymthe.2005.11.002
 [Y]  - CEKAITE, L. ET AL., "Gene Expression Analysis in Blood Cells in Response to Unmodified and 2'-Modified siRNA Reveals TLR- dependent and Independent Effects.", J. MOL. BIOL., (200701), vol. 365, no. 1, pages 90 - 108, XP005728210

DOI:   http://dx.doi.org/10.1016/j.jmb.2006.09.034
by applicantUS6906186
 US2007265438
 CN1651450
 WO2007051303
 US2006240554
 WO2009086558
 WO2010042877
 US7404969
 WO0003683
 US2004142025
 US2007042031
 US5885613
 US2006083780
 US5208036
 US5264618
 US5279833
 US5283185
 US5753613
 US5785992
 WO9610390
 US4376110
 US4452901
 US3817827
 US3850752
 US3901654
 US3935074
 US3984533
 US3996345
 US4034074
 US4098876
 US4683195
 US4683202
 US5998203
 GB2397818
 US2004192626
 US2005282188
 US2007135372
 US2005074771
 US2005043219
 US2005158727
 US2003130186
 US2004110296
 US2004249178
 US6753423
 US2005119470
 US2005107325
 US2005153337
 US2004167090
 US2005239739
 US5705385
 US5976567
 US5981501
 US6110745
 US6320017
 WO9640964
 WO2005026372
 US2003077829
 US2005008689
 US6774180
 US7053150
 US6586559
 US6852334
 WO0062813
 US2003203865
 US2002192275
 US2003180950
 US6756054
 US2005234232
 US2003229040
 US2002160038
 US2002012998
 US5908635
 WO0172283
 US2003026831
 US2002192274
 AU2003210303
 US2003108597
 WO0050008
 US2003198664
 US6207456
 US2003031704
 WO03057190
 WO03059322
 US2003129221
 US5756122
 US2003035829
 US2003072794
 US6200599
 EP1304160
 US6747014
 US2005037086
 US6013240
 US6620805
 US2004156909
 US2003220289
 WO9602655
 WO9521931
 US2006211643
 US2005222064
 US2003125281
 US2003185890
 WO03066069
 US2004071654
 US2004142475
 US2003157030
 US2005123600
 AU2002358514
 WO02096551
 US2004087024
 US6509323
 US6884789
 US7091192
 US7018609
 US5820873
 US4737323
 US6586410
 US6534484
 US2002072121
 WO2005007196
 WO2005121348
 WO2005120152
 WO2004002453
 US5286634
 US3993754
 US4145410
 US4235871
 US4224179
 US4522803
 US4588578
 US5756353
 US5804212
 US5725871
 US5780045
 US5641515
 US5580579
 US5792451
 US5426039
    - ELBASHIR ET AL., GENES DEV., (2001), vol. 15, pages 188 - 200
    - HAMMOND ET AL., NAT. REV. GENET., (2001), vol. 2, pages 110 - 119
    - NIGG, CURR. OPIN. CELL. BIOL., (1998), vol. 10, pages 776 - 783
    - HAMANAKA ET AL., J. BIOL. CHEM., (1995), vol. 270, pages 21086 - 21091
    - LANE ET AL., J. CELL. BIOL., (1996), vol. 135, pages 1701 - 1713
    - GOLSTEYN ET AL., J. CELL. BIOL., (1995), vol. 129, pages 1617 - 1628
    - ARNAUD ET AL., CHROMOSOMA, (1998), vol. 107, pages 424 - 429
    - KOTANI ET AL., MOL. CELL, (1998), vol. 1, pages 371 - 380
    - GOLSTEYN ET AL., J. CELL. SCI., (1994), vol. 107, pages 1509 - 1517
    - HAMANAKA ET AL., CELL. GROWTH DIFFER., (1994), vol. 5, pages 249 - 257
    - HOLTRICH ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1994), vol. 91, pages 1736 - 1740
    - LAKE ET AL., MOL. CELL. BIOL., (1993), vol. 13, pages 7793 - 7801
    - MUNDT ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (1997), vol. 239, pages 377 - 385
    - SMITH ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (1997), vol. 234, pages 397 - 405
    - WOLF ET AL., ONCOGENE, (1997), vol. 14, pages 543 - 549
    - YUAN ET AL., AM. J. PATHOL., (1997), vol. 150, pages 1165 - 1172
    - TOKUMITSU ET AL., INT. J. ONCOL., (1999), vol. 15, pages 687 - 692
    - KNECHT ET AL., CANCER RES., (1999), vol. 59, pages 2794 - 2797
    - ELEZ ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (2000), vol. 209, pages 352 - 356
    - JUDGE ET AL., MOL. THER., (2006), vol. 13, no. 3, pages 494 - 505
    - ZIMMERMAN ET AL., NATURE, (2006), vol. 441, pages 111 - 114
    - JUDGE ET AL., MOL. THER., (2006), vol. 13, pages 328 - 337
    - THOMAS ET AL., J. CLIN. ONCOL., (2005), vol. 23, pages 2892 - 2899
    - LLOVET ET AL., J. NATL. CANCER INST., (2008), vol. 100, pages 698 - 711
    - LLOVET ET AL., J. HEPATOL., (2008), vol. 48, no. 1, pages 20 - 37
    - STEELE ET AL., ANNALS SURGERY, (1989), vol. 210, pages 127 - 138
    - ELBASHIR ET AL., NATURE, (2001), vol. 411, pages 494 - 498
    - ZIMMERMANN ET AL., NATURE, (2006), vol. 441, pages 111 - 114
    - FOUGEROLLES ET AL., NAT. REV. DRUG DISCOV., (2007), vol. 6, pages 443 - 453
    - BEHLKE, MOL. THER., (2006), vol. 13, pages 644 - 670
    - SOUTSCHEK ET AL., NATURE, (2004), vol. 432, pages 173 - 178
    - HALL ET AL., NUCLEIC ACIDS RES., (2004), vol. 32, pages 5991 - 6000
    - MORRISSEY ET AL., HEPATOLOGY, (2005), vol. 41, pages 1349 - 1356
    - URBAN-KLEIN ET AL., GENE THER., (2005), vol. 12, pages 461 - 466
    - SCHIFFELERS ET AL., NUCLEIC ACIDS RES., (2004), vol. 32, page E149
    - HEIDEL ET AL., PROC. NATL. ACAD. SCI. USA, (2007), vol. 104, pages 5715 - 5721
    - MORRISSEY ET AL., NAT. BIOTECHNOL., (2005), vol. 23, pages 1002 - 1007
    - JUDGE ET AL., MOL. THER., (2006), vol. 13, pages 494 - 505
    - MAYER ET AL., CANCER LETTERS, (1990), vol. 53, pages 183 - 190
    - SEYMOUR, CRIT. REV. THER. DRUG CARRIER SYST., (1992), vol. 9, pages 135 - 187
    - BARR ET AL., NAT. REV. MOL. CELL BIOL., (2004), vol. 5, pages 429 - 440
    - TANIGUCHI ET AL., J. BIOL. CHEM., (2002), vol. 277, pages 48884 - 48888
    - STREBHARDT ET AL., NAT. REV. CANCER, (2006), vol. 6, pages 321 - 330
    - STEEGMAIER ET AL., CURR. BIOL., (2007), vol. 17, pages 316 - 322
    - LIU ET AL., PROC. NATL. ACAD. SCI. USA, (2003), vol. 100, pages 5789 - 5794
    - SPANKUCH ET AL., ONCOGENE, (2007), vol. 26, pages 5793 - 5807
    - YANG ET AL., PROC. NATL. ACAD. SCI. USA, (2002), vol. 99, pages 9942 - 9947
    - CALEGARI ET AL., PROC. NATL. ACAD. SCI. USA, (2002), vol. 99, page 14236
    - BYROM ET AL., AMBION TECHNOTES, (2003), vol. 10, no. 1, pages 4 - 6
    - KAWASAKI ET AL., NUCLEIC ACIDS RES., (2003), vol. 31, pages 981 - 987
    - KNIGHT ET AL., SCIENCE, (2001), vol. 293, pages 2269 - 2271
    - ROBERTSON ET AL., J. BIOL. CHEM., (1968), vol. 243, page 82
    - Current Protocols in Molecular Biology
    - SMITH; WATERMAN, ADV. APPL. MATH., (1981), vol. 2, page 482
    - NEEDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, page 443
    - PEARSON; LIPMAN, PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, page 2444
    - ALTSCHUL ET AL., NUC. ACIDS RES., (1977), vol. 25, pages 3389 - 3402
    - ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, pages 403 - 410
    - KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 5873 - 5787
    - BATZER ET AL., NUCLEIC ACID RES., (1991), vol. 19, page 5081
    - OHTSUKA ET AL., J BIOL. CHEM., (1985), vol. 260, pages 2605 - 2608
    - ROSSOLINI ET AL., MOL. CELL. PROBES, (1994), vol. 8, pages 91 - 98
    - ELBASHIR ET AL., GENES DEV., (2001), vol. 15, page 188
    - NYKANEN ET AL., CELL, (2001), vol. 107, page 309
    - ELBASHIR ET AL., EMBO J., (2001), vol. 20, pages 6877 - 6888
    - REYNOLDS ET AL., NATURE BIOTECH., (2004), vol. 22, no. 3, pages 326 - 330
    - KHVOROVA ET AL., CELL, (2003), vol. 115, pages 209 - 216
    - SCHWARZ ET AL., CELL, (2003), vol. 115, pages 199 - 208
    - LUO ET AL., BIOPHYS. RES. COMMUN., (2004), vol. 318, pages 303 - 310
    - BROWN ET AL., J. BIOL. CHEM., (1980), vol. 255, pages 4980 - 4983
    - RAINES ET AL., J. BIOL. CHEM., (1982), vol. 257, pages 5154 - 5160
    - BROOKS ET AL., CLIN. EXP. IMMUNOL., (1980), vol. 39, page 477
    - BOWEN-POPE ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, pages 2396 - 2400
    - KOHLER ET AL., NATURE, (1975), vol. 256, pages 495 - 497
    - BUHRING ET AL., HYBRIDOMA, (1991), vol. 10, no. 1, pages 77 - 78
    - GUBLER; HOFFMAN, GENE, (1983), vol. 25, pages 263 - 269
    - USMAN ET AL., J. AM. CHEM. SOC., (1987), vol. 109, page 7845
    - SCARINGE ET AL., NUCL. ACIDS RES., (1990), vol. 18, page 5433
    - WINCOTT ET AL., NUCL. ACIDS RES., (1995), vol. 23, pages 2677 - 2684
    - WINCOTT ET AL., METHODS MOL. BIO., (1997), vol. 74, page 59
    - LIN ET AL., J. AM. CHEM. SOC., (1998), vol. 120, pages 8531 - 8532
    - LOAKES, NUCL. ACIDS RES., (2001), vol. 29, pages 2437 - 2447
    - BEAUCAGE ET AL., TETRAHEDRON, (1993), vol. 49, page 1925
    - "Nucleic Acid Analogues: Synthesis and Properties", HUNZIKER ET AL., Modern Synthetic Methods, VCH, (1995), pages 331 - 417
    - "Novel Backbone Replacements for Oligonucleotides", MESMAEKER ET AL., Carbohydrate Modifications in Antisense Research, ACS, (1994), pages 24 - 39
    - SUN ET AL., NAT. BIOTECH., (2008), vol. 26, pages 1379 - 1382
    - LAGOS-QUINTANA ET AL., SCIENCE, vol. 294, pages 853 - 858
    - LAU ET AL., SCIENCE, vol. 294, pages 858 - 862
    - LEE ET AL., SCIENCE, vol. 294, pages 862 - 864
    - DENLI ET AL., NATURE, (2004), vol. 432, pages 231 - 235
    - BERNSTEIN ET AL., NATURE, (2001), vol. 409, pages 363 - 366
    - PREALL ET AL., CURR. BIOL., (2006), vol. 16, pages 530 - 535
    - GREGORY ET AL., CELL, (2005), vol. 123, pages 631 - 640
    - CHEN ET AL., BIOCONJ. CHEM., (2000), vol. 11, pages 433 - 437
    - ZHANG ET AL., J. CONTROL RELEASE, (2004), vol. 100, pages 165 - 180
    - LYNN ET AL., J. AM. CHEM. SOC., (2001), vol. 123, pages 8155 - 8156
    - KUKOWSKA-LATALLO ET AL., PROC. NATL. ACAD. SCI. USA, (1996), vol. 93, pages 4897 - 4902
    - TIERA ET AL., CURR. GENE THER., (2006), vol. 6, pages 59 - 71
    - STRAUBRINGER ET AL., METHODS ENZYMOL., (1983), vol. 101, page 512
    - MANNINO ET AL., BIOTECHNIQUES, (1988), vol. 6, page 682
    - NICOLAU ET AL., CRIT. REV. THER. DRUG CARRIER SYST., (1989), vol. 6, page 239
    - BEHR, ACC. CHEM. RES., (1993), vol. 26, page 274
    - CULVER, HUMAN GENE THERAPY, MARYANN LIEBERT, INC., (1994), pages 70 - 71
    - BRIGHAM ET AL., AM. J. SCI., (1989), vol. 298, page 278
    - ARNHEIM; LEVINSON, C&EN, (19901001), page 36
    - THE JOURNAL OFNIH RESEARCH, (1991), vol. 3, page 81
    - KWOH ET AL., PROC. NATL. ACAD. SCI. USA, (1989), vol. 86, page 1173
    - GUATELLI ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, page 1874
    - LOMELL ET AL., J. CLIN. CHEM., (1989), vol. 35, page 1826
    - LANDEGREN ET AL., SCIENCE, (1988), vol. 241, page 1077
    - VAN BRUNT, BIOTECHNOLOGY, (1990), vol. 8, page 291
    - WU; WALLACE, GENE, (1989), vol. 4, page 560
    - BARRINGER ET AL., GENE, (1990), vol. 89, page 117
    - SOOKNANAN; MALEK, BIOTECHNOLOGY, (1995), vol. 13, page 563
    - BEAUCAGE ET AL., TETRAHEDRON LETTS., (1981), vol. 22, pages 1859 - 1862
    - NEEDHAM VANDEVANTER ET AL., NUCLEIC ACIDS RES., (1984), vol. 12, page 6159
    - PEARSON ET AL., J. CHROM., (1983), vol. 255, pages 137 - 149
    - MAXAM; GILBERT, Methods in Enzymology, ACADEMIC PRESS, (1980), vol. 65, page 499
    - ANGERER ET AL., METHODS ENZYMOL., (1987), vol. 152, page 649
    - GILLIET ET AL., J. EXP. MED., vol. 195, pages 953 - 958
    - ELBASHIR, S.M. ET AL., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", NATURE, (2001), vol. 411, doi:doi:10.1038/35078107, pages 494 - 498, XP002529540

DOI:   http://dx.doi.org/10.1038/35078107
    - JUDGE, A.D. ET AL., "Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA", NAT BIOTECHNOL, (2005), vol. 23, doi:doi:10.1038/nbt1081, pages 457 - 462, XP002371480

DOI:   http://dx.doi.org/10.1038/nbt1081
    - HORNUNG, V. ET AL., "Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7", NAT MED, (2005), vol. 11, pages 263 - 270
    - KLEINMAN, M.E. ET AL., "Sequence and target-independent angiogenesis suppression by siRNA via TLR3", NATURE, (2008), vol. 452, pages 591 - 597
    - HORNUNG, V. ET AL., "5'-Triphosphate RNA is the ligand for RIG-I", SCIENCE, (2006), vol. 314, doi:doi:10.1126/science.1132505, pages 994 - 997, XP002428032

DOI:   http://dx.doi.org/10.1126/science.1132505
    - MARQUES, J.T. ET AL., "A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells", NAT BIOTECHNOL, (2006), vol. 24, doi:doi:10.1038/nbt1205, pages 559 - 565, XP002447307

DOI:   http://dx.doi.org/10.1038/nbt1205
    - KRIEG, A.M., "Therapeutic potential of Toll-like receptor 9 activation", NAT REV DRUG DISCOV, (2006), vol. 5, doi:doi:10.1038/nrd2059, pages 471 - 484, XP008109144

DOI:   http://dx.doi.org/10.1038/nrd2059
    - VON MARSCHALL, Z. ET AL., "Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis", JNATL CANCER INST, (2003), vol. 95, pages 437 - 448
    - LANUTI, M. ET AL., "Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models", CANCER RES, (2000), vol. 60, pages 2955 - 2963
    - BUHTOIAROV, I.N.; LUM, H.D.; BERKE, G.; SONDEL, P.M.; RAKHMILEVICH, A.L., "Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects", JIMMUNOL, (2006), vol. 176, pages 309 - 318
    - JUDGE, A.; MACLACHLAN, I., "Overcoming the innate immune response to small interfering RNA", HUM GENE THER, (2008), vol. 19, doi:doi:10.1089/hum.2007.179, pages 111 - 124, XP055046609

DOI:   http://dx.doi.org/10.1089/hum.2007.179
    - MICHIE, H.R. ET AL., "Detection of Circulating Tumor Necrosis Factor after Endotoxin Administration", N. ENGL. J. MED., (1988), vol. 318, pages 1481 - 1486
    - STEVENSON, H.C. ET AL., "A phase I evaluation ofpoly(I,C)-LC in cancer patients", JBIOL RESPONSE MOD., (1985), vol. 4, pages 650 - 655
    - SCHLEE, M.; BARCHET, W.; HORNUNG, V.; HARTMANN, G., "Beyond double-stranded RNA-type I IFN induction by 3pRNA and other viral nucleic acids", CURR TOP MICROBIOL IMMUNOL, (2007), vol. 316, pages 207 - 230
    - POECK, H. ET AL., "5'-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma", NAT MED., (2008), vol. 14, doi:doi:10.1038/NM.1887, pages 1256 - 1263, XP002535217

DOI:   http://dx.doi.org/10.1038/NM.1887
    - MANOHARAN, M., "RNA interference and chemically modified small interfering RNAs", CURR. OPIN. CHEM. BIOL., (2004), vol. 8, doi:doi:10.1016/j.cbpa.2004.10.007, pages 570 - 579, XP004649493

DOI:   http://dx.doi.org/10.1016/j.cbpa.2004.10.007
    - MORRISSEY, D.V. ET AL., "Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs", NAT BIOTECHNOL, (2005), vol. 23, doi:doi:10.1038/nbt1122, pages 1002 - 1007, XP008157520

DOI:   http://dx.doi.org/10.1038/nbt1122
    - JUDGE, A.D.; BOLA, G.; LEE, A.C.; MACLACHLAN, I., "Design of non- inflammatory synthetic siRNA mediating potent gene silencing in vivo", MOL THER, (2006), vol. 13, pages 494 - 505
    - KNIGHT, S.D.; PARRISH, C.A., "Recent progress in the identification and clinical evaluation of inhibitors of the mitotic kinesin KSP", CURR TOP MED CHEM, (2008), vol. 8, pages 888 - 904
    - STREBHARDT, K.; ULLRICH, A., "Targeting polo-like kinase 1 for cancer therapy", NAT REV CANCER, (2006), vol. 6, doi:doi:10.1038/nrc1841, pages 321 - 330, XP002419975

DOI:   http://dx.doi.org/10.1038/nrc1841
    - TAO, W. ET AL., "Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage", CANCER CELL, (2005), vol. 8, doi:doi:10.1016/j.ccr.2005.06.003, pages 49 - 59, XP003006609

DOI:   http://dx.doi.org/10.1016/j.ccr.2005.06.003
    - BARR, F.A.; SILLJE, H.H.; NIGG, E.A., "Polo-like kinases and the orchestration of cell division", NAT REV MOL CELL BIOL, (2004), vol. 5, pages 429 - 440
    - STEEGMAIER, M. ET AL., "BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo", CURR BIOL, (2007), vol. 17, doi:doi:10.1016/j.cub.2006.12.037, pages 316 - 322, XP005890944

DOI:   http://dx.doi.org/10.1016/j.cub.2006.12.037
    - LIU, X.; ERIKSON, R.L, "Polo-like kinase (Plk)l depletion induces apoptosis in cancer cells", PROC NATL ACAD SCI USA, (2003), vol. 100, pages 5789 - 5794
    - SPANKUCH, B.; KURUNCI-CSACSKO, E.; KAUFMANN, M.; STREBHARDT, K., "Rational combinations of siRNAs targeting Plkl with breast cancer drugs", ONCOGENE, (2007), vol. 26, doi:doi:10.1038/sj.onc.1210355, pages 5793 - 5807, XP055017771

DOI:   http://dx.doi.org/10.1038/sj.onc.1210355
    - ZIMMERMANN, T.S. ET AL., "RNAi-mediated gene silencing in non-human primates", NATURE, (2006), vol. 441, pages 111 - 114
    - DE FOUGEROLLES, A.; VORNLOCHER, H.P.; MARAGANORE, J.; LIEBERMAN, J., "Interfering with disease: a progress report on siRNA-based therapeutics", NAT REV DRUG DISCOV, (2007), vol. 6, pages 443 - 453
    - BEHLKE, M.A., "Progress towards in vivo use of siRNAs", MOL THER., (2006), vol. 13, doi:doi:10.1016/j.ymthe.2006.01.001, pages 644 - 670, XP005358601

DOI:   http://dx.doi.org/10.1016/j.ymthe.2006.01.001
    - URBAN-KLEIN, B.; WERTH, S.; ABUHARBEID, S.; CZUBAYKO, F.; AIGNER, A., "RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo", GENE THER., (2005), vol. 12, pages 461 - 466, XP003002818
    - SCHIFFELERS R.M ET AL., "Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle", NUCLEIC ACIDS RES., (2004), vol. 32, page E149, XP002403860
    - HEIDEL, J.D. ET AL., "Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA", PROC NATL ACAD SCI US A, (2007), vol. 104, doi:doi:10.1073/PNAS.0701458104, pages 5715 - 5721, XP002609879

DOI:   http://dx.doi.org/10.1073/PNAS.0701458104
    - SANTEL, A. ET AL., "A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium", GENE THER, (2006), vol. 13, doi:doi:10.1038/sj.gt.3302777, pages 1222 - 1234, XP002459352

DOI:   http://dx.doi.org/10.1038/sj.gt.3302777
    - MAYER, L.; BALLY, M.; CULLIS, P.; WILSON, S.; EMERMAN, J., "Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and anti- tumor efficacy in the SC 115 murine mammary tumor", CANCER LETTERS, (1990), vol. 53, pages 183 - 190
    - SEYMOUR, L.W., "Passive tumor targeting of soluble macromolecules and drug conjugates", CRIT REV THER DRUG CARRIER SYST, (1992), vol. 9, pages 135 - 187
    - CHONO, S.; LI, S.D.; CONWELL, C.C.; HUANG, L, "An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor", J CONTROL RELEASE, (2008), vol. 131, doi:doi:10.1016/j.jconrel.2008.07.006, pages 64 - 69, XP025506370

DOI:   http://dx.doi.org/10.1016/j.jconrel.2008.07.006
    - PEER, D.; PARK, E.J.; MORISHITA, Y.; CARMAN, C.V.; SHIMAOKA, M, "Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target", SCIENCE, (2008), vol. 319, doi:doi:10.1126/science.1149859, pages 627 - 630, XP002531464

DOI:   http://dx.doi.org/10.1126/science.1149859
    - WEIL, D.; GARCON, L.; HARPER, M.; DUMENIL, D.; DAUTRY, F.; KRESS, M., "Targeting the kinesin Eg5 to monitor siRNA transfection in mammalian cells", BIOTECHNIQUES, (2002), vol. 33, pages 1244 - 1248, XP001207431
    - SOUTSCHEK, J. ET AL., "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs", NATURE, (2004), vol. 432, doi:doi:10.1038/nature03121, pages 173 - 178, XP055298595

DOI:   http://dx.doi.org/10.1038/nature03121
    - ELBASHIR, S.M.; LENDECKEL, W.; TUSCHL, T., "RNA interference is mediated by 2 1 - and 22-nucleotide RNAs", GENES DEV., (2001), vol. 15, doi:doi:10.1101/gad.862301, pages 188 - 200, XP002206453

DOI:   http://dx.doi.org/10.1101/gad.862301
    - MATRANGA, C.; TOMARI, Y.; SHIN, C.; BARTEL, D.P.; ZAMORE, P.D., "Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes", CELL, (2005), vol. 123, doi:doi:10.1016/j.cell.2005.08.044, pages 607 - 620, XP002484663

DOI:   http://dx.doi.org/10.1016/j.cell.2005.08.044
    - LEUSCHNER, P.J.; AMERES, S.L.; KUENG, S.; MARTINEZ, J, "Cleavage of the siRNA passenger strand during RISC assembly in human cells", EMBO REP, (2006), vol. 7, doi:doi:10.1038/sj.embor.7400637, pages 314 - 320, XP002443952

DOI:   http://dx.doi.org/10.1038/sj.embor.7400637
    - PRAKASH, T. ET AL., "Positional effect of chemical modifications on short interference RNA activity in mammalian cells", J. MED. CHEM., (2005), vol. 48, doi:doi:10.1021/jm050044o, pages 4247 - 4253, XP008155072

DOI:   http://dx.doi.org/10.1021/jm050044o
    - YAO, X. ET AL., "A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis", CLIN CANCER RES, (2003), vol. 9, pages 2719 - 2726
    - SAKOWITZ, R. ET AL., "Antitumor activity of kinesin inhibitor", CANCER RESEARCH, (2004), vol. 64, doi:doi:10.1158/0008-5472.CAN-03-3839, pages 3276 - 3280, XP002476970

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-03-3839
    - LENART, P. ET AL., "The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1", CURR BIOL, (2007), vol. 17, doi:doi:10.1016/j.cub.2006.12.046, pages 304 - 315, XP005890943

DOI:   http://dx.doi.org/10.1016/j.cub.2006.12.046
    - SPANKUCH-SCHMITT, B.; BEREITER-HAHN, J.; KAUFMANN, M.; STREBHARDT, K., "Effect of RNA silencing of polo-like kinase- (PLK1) on apoptosis and spindle formation in human cancer cells", JNATL CANCER INST, (2002), vol. 94, pages 1863 - 1877, XP002998259
    - AMBEGIA, E. ET AL., "Stabilized plasmid-lipid particles containing PEG- diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression", BIOCHIMICA ET BIOPHYSICA ACTA, (2005), vol. 1669, doi:doi:10.1016/j.bbamem.2005.02.001, pages 155 - 163, XP004890715

DOI:   http://dx.doi.org/10.1016/j.bbamem.2005.02.001
    - HEYES, J.; HALL, K.; TAILOR, V.; LENZ, R.; MACLACHLAN, I, "Synthesis and characterisation of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery", JOURNAL OF CONTROLLED RELEASE, (2006), vol. 112, doi:doi:10.1016/j.jconrel.2006.02.012, pages 280 - 290, XP024957509

DOI:   http://dx.doi.org/10.1016/j.jconrel.2006.02.012
    - KRIEG, A.M., "CpG motifs in bacterial DNA and their immune effects", ANNU. REV. IMMUNOL., (2002), vol. 20, doi:doi:10.1146/annurev.immunol.20.100301.064842, pages 709 - 760, XP009016455

DOI:   http://dx.doi.org/10.1146/annurev.immunol.20.100301.064842
    - CASTRO, J.E. ET AL., "Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference", LEUKEMIA, (2006), vol. 20, pages 680 - 688
    - DIEBOLD, S.S. ET AL., "Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides", EURJIMMUNOL, (2006), vol. 36, doi:doi:10.1002/eji.200636617, pages 3256 - 3267, XP008101287

DOI:   http://dx.doi.org/10.1002/eji.200636617
    - DER, S.D.; ZHOU, A.; WILLIAMS, B.R.; SILVERMAN, R.H., "Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays", PROC NATL ACAD SCI USA, (1998), vol. 95, doi:doi:10.1073/pnas.95.26.15623, pages 15623 - 15628, XP002229726

DOI:   http://dx.doi.org/10.1073/pnas.95.26.15623
    - GEISS, G. ET AL., "A comprehensive view of regulation of gene expression by double-stranded RNA-mediated cell signaling", JBIOL CHEM, (2001), vol. 276, pages 30178 - 30182, XP002453475
    - SARKAR, S.N.; SMITH, H.L.; ROWE, T.M.; SEN, G.C., "Double-stranded RNA signaling by Toll-like receptor 3 requires specific tyrosine residues in its cytoplasmic domain.", JBIOL CHEM, (2003), vol. 278, pages 4393 - 4396
    - CZAUDERNA, F. ET AL., "Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells", NUCL. ACIDS RES., (2003), vol. 31, pages 2705 - 2716
    - SANTEL, A. ET AL., "RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy", GENE THER, (2006), vol. 13, doi:doi:10.1038/sj.gt.3302778, pages 1360 - 1370, XP002443322

DOI:   http://dx.doi.org/10.1038/sj.gt.3302778
    - JOHNSON, E.F.; STEWART, K.D.; WOODS, K.W.; GIRANDA, V.L.; LUO, Y., "Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity", BIOCHEMISTRY, (2007), vol. 46, doi:doi:10.1021/bi7008745, pages 9551 - 9563, XP002537861

DOI:   http://dx.doi.org/10.1021/bi7008745
    - MALUMBRES, M.; BARBACID, M., "Cell cycle kinases in cancer", CURR OPIN GENET DEV, (2007), vol. 17, doi:doi:10.1016/j.gde.2006.12.008, pages 60 - 65, XP005736996

DOI:   http://dx.doi.org/10.1016/j.gde.2006.12.008
    - MCINNES, C. ET AL., "Inhibitors of Polo-like kinase reveal roles in spindle- pole maintenance", NAT CHEM BIOL, (2006), vol. 2, pages 608 - 617
    - BARTLETT, D.W.; DAVIS, M.E., "Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging", NUCLEIC ACIDS RES, (2006), vol. 34, pages 322 - 333
    - LLOVET, J.M.; BRUIX, J., "Novel advancements in the management of hepatocellular carcinoma in 2008", JHEPATOL, (2008), vol. 48, no. I, doi:doi:10.1016/j.jhep.2008.01.022, pages S20 - 37, XP022534900

DOI:   http://dx.doi.org/10.1016/j.jhep.2008.01.022
    - SCHWARZ, D.S. ET AL., "Asymetry in the assembly of the RNAi enzyme complex", CELL, (2003), vol. 115, pages 119 - 208
    - GILLIET, M. ET AL., "The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony- stimulating factor", J EXP MED, (2002), vol. 195, doi:doi:10.1084/jem.20020045, pages 953 - 958, XP055248091

DOI:   http://dx.doi.org/10.1084/jem.20020045
 US20010744103
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.